Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain

Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain

Whether the FDA requires completion of a study to look at testicular toxicity before approval could dictate whether the drug launches next year or as late as 2022, an analyst wrote.

Source: https://ift.tt/2JX9tbE